Physician profile
Stanya Smith
NPI 1205845732
$2,181.78
in general payments reported to CMS, 2019-2025
19 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2021: $549 · 2022: $858 · 2023: $147 · 2024: $277 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Education: $22.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.10 |
| Education | $22.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $407.59 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $364.11 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $126.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $125.01 | 2021 | |
| Emd Serono, INC. | $125.00 | 2022 | |
| Genentech USA, INC. | $125.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $125.00 | 2021 | |
| Celgene Corporation | $124.87 | 2021 | |
| Amgen INC. | $121.57 | 2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $119.99 | 2022 | |
| Biogen, INC. | $111.59 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $109.80 | 2021 | |
| Acorda Therapeutics, INC | $101.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.28 | 2019 | |
| Boston Scientific Corporation | $27.46 | 2025 | Watchman Access System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $14.67 | 2024 | |
| Mdd US Operations, LLC | $13.97 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanya Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.